Introduction {#s1}
============

Aromatase inhibitors (AIs) improve survival compared with tamoxifen and are the preferred adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer \[[@B1]\]. Previous large adjuvant endocrine trials have reported no significant decrease in overall health-related quality of life (HRQOL) during adjuvant AI therapy \[[@B2]--[@B4]\]. Despite these data, in multiple research and clinical practice settings early discontinuation is common, ranging from 30% to 70% \[[@B5]\]. Although reasons for early discontinuation are multifactorial, data suggest that up to 30% of patients discontinue AI therapy because of adverse symptoms, most commonly arthralgias \[[@B6], [@B7]\].

Multiple studies have explored predictors of early discontinuation on the basis of baseline demographic and/or clinicopathologic features; however, inconsistent results between studies have made it difficult for clinicians to accurately predict which patients are at greatest risk for early discontinuation. Interestingly, one report found that although a baseline history of anxiety or depression was not associated with early discontinuation, treatment for anxiety that developed after initiation of endocrine therapy was associated with early discontinuation \[[@B8]\]. This latter observation suggests that a change in symptom burden early in the course of therapy could be a predictor for discontinuation and that early identification could possibly allow for earlier intervention.

The Exemestane and Letrozole Pharmacogenetics (ELPh) trial was a randomized study to investigate the pharmacogenetic influences on the effects of AI therapy; it included prospective patient-reported outcome (PRO) measures throughout the initial 24-months of AI therapy. Measures included were for global HRQOL, depression, anxiety, and symptom burden. We previously reported a statistically significant difference in time to treatment discontinuation in this cohort, with a shorter time to discontinuation for those treated with exemestane compared with letrozole \[[@B6]\]. The primary objective of this exploratory analysis was to determine whether early changes in PRO measures predicted early discontinuation and compare longitudinal changes in PROs by two distinct AIs. To examine the mechanism underlying development of PROs during AI therapy, we also examined the association between changes in PROs and various biochemical factors. On the basis of previous data \[[@B9]\], hypotheses were as follows: (a) there would be no significant difference in PRO measures between AIs, (b) negative early changes in PROs would predict early discontinuation, and (c) greater suppression of estrogen metabolites would be associated with greater negative changes in PROs.

Materials and Methods {#s2}
=====================

Study Participants {#s3}
------------------

Postmenopausal women with stage 0--III hormone receptor-positive breast cancer who were initiating treatment with an AI were eligible for enrollment on the ELPh trial. Details of the trial have been previously published ([ClinicalTrials.gov](http://ClinicalTrials.gov) NCT00228956) \[[@B6], [@B10]\]. In brief, all indicated surgery, chemotherapy, and/or radiation therapy were completed before enrollment. Prior tamoxifen therapy was permitted. No patients could have previously received AI therapy for any reason. Supportive care as directed by the clinical team was permitted for management of any treatment-emergent toxicity and was not protocol driven except for offering patients the option to cross over to the alternative AI. The institutional review boards at all three participating sites (Johns Hopkins University, Indiana University, University of Michigan) approved the clinical trial. Patients were required to provide written informed consent before undergoing study-related procedures.

Study Procedures {#s4}
----------------

Patients were randomly assigned in a 1:1 ratio to treatment with exemestane (Aromasin; Pfizer, New York, NY), 25 mg orally daily, or letrozole (Femara; Novartis, Basel, Switzerland), 2.5 mg orally daily. Randomization was stratified by prior chemotherapy, prior tamoxifen, and bisphosphonate use. At baseline and after 1, 3, 6, 12, and 24 months, patients were clinically evaluated and completed PRO questionnaires (see next section). Blood samples were collected at baseline and after 3 months of therapy for evaluation of estrogen metabolites and pharmacokinetics (PK).

PRO Questionnaires {#s5}
------------------

Validated tools for HRQOL, depression, anxiety, and symptom burden were used. Specifically, HRQOL was assessed by using the EuroQOL Visual Analog Scale (VAS). The EuroQOL VAS is one component of the EQ-5D; this 20-cm, Cantril-like ladder scale ranging from 0 (death) to 100 (best health) has demonstrated reliability and validity in populations with cancer \[[@B11]\]. The minimally important difference for the EuroQOL VAS is 7--12 \[[@B12]\]. Depression was assessed with the Center for Epidemiologic Studies--Depression (CESD) tool, a 20-item self-report tool that evaluates for the presence and severity of depressive symptoms. Scores range from 0 to 60, with scores of 16 or higher indicating high depressive symptoms \[[@B13]\]. Anxiety was assessed with the anxiety subscale of the Hospital Anxiety and Depression Scale (HADSA). This is a brief 7-item tool, and scores range from 0 to 21; scores of 8 or higher indicate anxiety \[[@B14]\]. A 47-item tool, composed largely of items from the Breast Cancer Prevention Trial Symptom Checklist (BCPT-SCL) \[[@B15]\], assessed general symptom burden ([supplemental online Table 1](http://theoncologist.alphamedpress.org/lookup/suppl/doi:10.1634/theoncologist.2015-0349/-/DC1)). Scores for each item range from 0 to 4, with a higher score indicating worse symptom burden. Of the 47 items assessed, the current analysis of general symptom burden used 34 items analyzed as six separate symptom clusters (weight/body image, vasomotor, vulvovaginal, musculoskeletal, cognitive, and mood) developed by using methods described later in the text.

Laboratory Studies {#s6}
------------------

As previously described, serum samples obtained at baseline and at 3 months were assayed for estradiol (E2), estrone-1-sulfate (E1S), and estrone (E1) by using an ultrasensitive gas chromatography/tandem mass spectroscopy assay \[[@B16]\]. The lower limits of quantification were 0.625 pg/mL for E2, 2.88 pg/mL for E1S, and 1.56 pg/mL for E1. Serum concentrations of exemestane and letrozole were measured at baseline and follow-up at 3 months (Z. Desta, personal communication) \[[@B17]\].

Statistical Analysis {#s7}
--------------------

In this exploratory analysis, the first objective was to compare early changes in PRO mean scores from baseline to months 1, 3, and 6 among patients who continued therapy through 24 months (persistent group) compared with those who discontinued before 24 months (nonpersistent) by using the Wilcoxon rank-sum test. In addition, we also analyzed whether the PRO measures predicted for time to discontinuation, where discontinuation of the initial AI therapy before 24 months was due to the development of intolerable toxicity (as reported by the patient as the primary cause of treatment discontinuation). To account for nonrandom dropout, a joint mixed-effects/survival model was used to estimate the effect of the change in PROs over 24 months on AI discontinuation. All PROs were modeled as continuous variables. Natural cubic splines were used in modeling time for all models with two to four knots (polynomial in time to allow for nonlinearity of association between time and PRO).

For the symptom clusters, we ran a confirmatory factor analysis at baseline to confirm the grouping of items based on the BCPT-SCL eight-symptom scale \[[@B18]\] and found high levels of goodness of fit for all clusters except the vulvovaginal cluster. Specifically, for the five other symptom clusters, the root mean square error of approximation was 0.043 (acceptable models use \<0.06) and the comparative fit index was 0.93 (acceptable, \>0.90). For each symptom cluster, the outcome is the square root (for distributional purposes in our mixed models) of the sum of the questions in each cluster and the average score per cluster for each time point. If a woman did not answer every question in the cluster, we used the average of those questions that she did answer.

For the second objective, we analyzed the changes from baseline in HRQOL, psychological distress, and symptom burden during the 24-month study period between AIs. PRO evaluation was missing at any time point after the patient had discontinued the AI. Mean change scores from baseline to each follow-up time point for those who had not yet discontinued were compared between treatment groups for all PRO domains and analyzed by using the Wilcoxon rank-sum test. A negative mean change in PRO indicates the score decreased from baseline and a positive mean change in PRO indicates the score increased from baseline. Associations between baseline variables of interest, including age, race, body mass index (BMI), prior use of tamoxifen, prior use of chemotherapy (yes vs. no and taxane vs. no taxane) and changes in PROs were assessed by using Spearman correlation for continuous variables and Wilcoxon rank-sum test for categorical variables.

Estrogen levels were measured at baseline and 3 months by using estrone sulfate, estradiol, and estrone. The correlations between the absolute estrogen level at 3 months and the change in estrogen from baseline to 3 months with the change in EuroQOL VAS, CESD, HADSA, and symptom clusters were examined by using Spearman correlation. Only one measure of PK data was available (taken at 3 months), so the drug PK level at 3 months was correlated to the change in PRO from baseline to 3 months using Spearman correlation. Multiple comparisons were not controlled for because of the exploratory nature of the analysis. Statistical analyses were conducted using SAS v9.3 (SAS Institute, Inc, Cary, NC, <http://www.sas.com>).

Results {#s8}
=======

Patient Characteristics {#s9}
-----------------------

Five hundred three patients signed informed consent. Three patients withdrew from study participation before randomization ([Fig. 1](#F1){ref-type="fig"}). Of the 500 eligible patients, 252 (50.4%) were randomly assigned to letrozole and 248 (49.6%) to exemestane. Ten patients (4%) were not included in the current analysis: 5 in each treatment arm because of no time on drug (*n* = 7), premenopausal status (*n* = 2), and no completed PRO data (*n* = 1). Baseline characteristics for the 490 patients in the current analysis are listed in [Table 1](#T1){ref-type="table"}. Most patients were white (*n* = 434 \[88%\]), nearly half had received adjuvant chemotherapy (*n* = 222 \[45%\]), and 178 (36%) had been treated with tamoxifen. Baseline scores for all PROs were not significantly different between treatment arms, as shown in [supplemental online Table 2](http://theoncologist.alphamedpress.org/lookup/suppl/doi:10.1634/theoncologist.2015-0349/-/DC1).

![Consolidated Standards of Reporting Trials diagram.\
Abbreviation: PRO, patient-reported outcome.](theoncologist_15349_f1){#F1}

###### 

Baseline demographic characteristics (*n* = 490)
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Longitudinal Effects of AI Therapy on PROs {#s10}
------------------------------------------

Mean change by drug from baseline to each time point for EuroQOL VAS, CESD, and HADSA are shown in [supplemental online Figure 1A--1C](http://theoncologist.alphamedpress.org/lookup/suppl/doi:10.1634/theoncologist.2015-0349/-/DC1), respectively. Although statistically significant differences between AIs were observed in mean change from baseline on the EuroQOL VAS at 6 months (−3.27 for exemestane vs. −0.38 for letrozole; *p* = .03) and CESD at 3 months (1.28 for exemestane vs. −0.14 for letrozole; *p* = .01), these were isolated findings and not consistent over time or symptom domain. No other significant differences in mean changes from baseline to any time point during the 24-month study period were found between treatment arms for these measures. Mean change from baseline to each time point for the six symptom clusters are shown in [supplemental online Table 3](http://theoncologist.alphamedpress.org/lookup/suppl/doi:10.1634/theoncologist.2015-0349/-/DC1). Significant differences between drugs were found in the weight/body image, musculoskeletal, and cognitive symptom clusters; however, the differences were uncommonly and inconsistently observed during the study period.

Changes in PRO and AI Early Discontinuation {#s11}
-------------------------------------------

Of the 490 patients analyzed, 156 (32%) patients discontinued AI treatment before 24 months because of toxicity. Of those, 88 (36.2%) randomly assigned to exemestane and 68 (27.5%) randomly assigned to letrozole discontinued therapy (*p* = .039). Forty-seven additional patients discontinued for reasons other than toxicity, such as recurrence, nonadherence with study procedures, and ovarian function recovery. Early changes in PRO mean scores (EuroQOL VAS, CESD, HADSA, and musculoskeletal \[MSK\] symptom cluster) from baseline to months 1, 3, and 6 by those who continued therapy until 24 months (persistent group) compared with those who discontinued before 24 months (nonpersistent) are shown in [Figure 2A--2D](#F2){ref-type="fig"}. Women who were nonpersistent were more likely to have worse Euro QOL VAS and MSK symptom cluster scores at all early time points compared with those that were persistent. No early differences in CESD or HADSA were observed.

![Mean changes from baseline in outcome measures by persistence. **(A):** EuroQOL VAS. Positive mean change in quality of life indicates improvement from baseline. Mean (±SD) baseline EuroQOL scores: persistent, 83.9 ± 12.14; not persistent, 84.8 ± 12.58 (*p* = .21). *p* value by Wilcoxon test. ∗, Statistically significant. QOL VAS range, 0--100 (100 indicating best imaginable health state). **(B):** CESD. Positive mean change in CES-D indicates improvement from baseline. Mean baseline CES-D scores: persistent, 7.5 ± 6.73; not persistent, 9.2 ± 8.10; *p* = .036. *p* value by Wilcoxon test; ∗, Statistically significant. CESD range, 0--60 (≥16 suggests clinical depression). **(C):** HADSA. Positive mean change in HADSA indicates improvement from baseline. Mean baseline HADS-A scores: persistent, 3.90 ± 3.03; not persistent, 4.4 ± 3.28; *p* = .11. *p* value by Wilcoxon test. HADSA range, 0--21 (≥8 suggests clinical anxiety). **(D):** MSK symptom cluster. Positive mean change in MSK symptom cluster indicates worse from baseline. Mean baseline MSK symptom cluster scores: persistent, 0.51 ± 0.049; not persistent, 0.62 ± 0.53; *p* = .012. *p* value by Wilcoxon test. ∗, Statistically significant. MSK symptom cluster range, 0--4.\
Abbreviations: CESD, Centers for Epidemiologic Studies--Depression; HADSA, anxiety scale of the Hospital Anxiety and Depression Scale; MSK, musculoskeletal; VAS, Visual Analog Scale.](theoncologist_15349_f2){#F2}

[Table 2](#T2){ref-type="table"} demonstrates the findings of the joint mixed-effects model used to estimate the effect of change in PROs on early discontinuation of AIs. Worsening in EuroQOL VAS was associated with increased risk for early discontinuation (hazard ratio \[HR\], 2.77; 95% confidence interval \[CI\], 2.72--2.81; *p* = .015). Worsening in depression (CESD) and anxiety (HADSA) scores was weakly associated with early discontinuation (HR, 1.04 \[95% CI, 1.01--1.06; *p* = .001\] and 1.04 \[95% CI, 1.01--1.06; *p* = .006\], respectively). Worsening in the musculoskeletal, cognitive, mood, and weight/body image clusters was also associated with increased risk for early discontinuation. Of these, the musculoskeletal symptom cluster was most highly associated with increased risk for early discontinuation (HR, 4.39; 95% CI, 2.4--8.02; *p* \< .0001).

###### 

Effect of the change in patient-reported outcome scores on early discontinuation of aromatase inhibitor treatment
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Predictors of Changes in PROs During AI Therapy {#s12}
-----------------------------------------------

Prior use of tamoxifen was not associated with any significant difference in EuroQOL VAS, CESD, or HADSA throughout the study period except EuroQOL VAS at 3 months (−3.1 for prior tamoxifen vs. −0.54 for no tamoxifen; *p* = .032) (data not shown). Compared with no prior tamoxifen use, prior tamoxifen use was associated with greater worsening in the musculoskeletal symptom cluster, lesser worsening at 3 months in the mood symptom cluster, and lesser worsening in the vasomotor symptom cluster throughout the study period. Prior exposure to chemotherapy or taxane compared with no such exposure was associated with a lesser worsening in the vasomotor symptom cluster and a greater worsening in the vulvovaginal symptom cluster (data not shown). Neither prior chemotherapy nor taxane exposure was associated with a significant change in EuroQOL VAS, CESD, or HADSA. No difference in the musculoskeletal symptom cluster was observed in patients with prior taxane exposure. No statistically significant associations were identified between change in any PRO measure during the 24-month study period and race, age, or BMI (data not shown).

Effect of Estrogen Metabolism and AI Pharmacokinetics on PROs {#s13}
-------------------------------------------------------------

We examined correlations between change in PROs and change in both serum estrogen metabolite concentrations (estradiol, estrone, estrogen sulfate) and AI concentration. No clinically relevant associations were found ([supplemental online Table 4](http://theoncologist.alphamedpress.org/lookup/suppl/doi:10.1634/theoncologist.2015-0349/-/DC1)).

Discussion {#s14}
==========

Compared with tamoxifen, upfront or sequential therapy with an AI is associated with improved disease-free and overall survival in postmenopausal women with hormone receptor-positive breast cancer \[[@B1], [@B19]\]. In the ELPh clinical trial, one third of patients discontinued AI treatment because of patient-reported intolerable symptom burden. We were able to identify early changes in PROs in the cohort that ultimately stopped as a result of treatment toxicity. These findings are consistent with a recent retrospective cohort study that found joint pain predicted for early AI discontinuation \[[@B20]\]. The ability to identify patients with high likelihood of developing intolerable adverse effects could have clinical implications for proactive symptom management strategies to minimize early discontinuation and improve adherence to life-prolonging therapies. In a feature unique to this analysis, we also explored biochemical changes and demographic variables that affected changes in PRO measures and could provide a mechanistic explanation for the development of the changes; however, none showed a consistent effect.

One challenge of studies of change in PROs during therapy is missing data associated with early treatment discontinuation. This is particularly true with AI therapy, for which a high rate of early discontinuation with therapy due to toxicity has been reported \[[@B6]\]. Bias can occur when women with the greatest symptom burden discontinue therapy early and do not contribute to the longitudinal PRO analyses. In the current study, most of the 32% who discontinued did so because of adverse symptoms at a median time of 6.1 months and therefore failed to contribute to the subsequent PRO analyses.

Although we observed a greater worsening in EuroQOL VAS and musculoskeletal symptom burden early in the treatment course (baseline to months 1, 3, and 6) in those who subsequently discontinued therapy compared with those who remained on therapy, nonrandom dropout and multiple comparisons limit these analyses. We attempted to account for the effect of missing data by using a joint mixed-effects/survival model. Our exploratory analysis suggests that the progressive development of symptoms over time is associated with early discontinuation of AI therapy. Most notably, increasing scores in the musculoskeletal symptom cluster over time were associated with a substantially increased risk for discontinuing AI therapy early.

Despite the prevalence and negative effect of arthralgias on HRQOL, the true mechanism for these symptoms remains to be fully understood. One hypothesis is based on the influence of estrogen depletion. This is, in part, supported by findings from a survey study finding that shorter interval since the onset of menopause was associated with higher AI-associated arthralgia burden, suggesting that these women might have had a larger decrease in absolute estrogen levels \[[@B21]\]. Although this is an interesting finding, our current data and prior work from our group \[[@B22]\] have not observed an association with absolute change in estrogen or estrogen metabolites following AI therapy and the onset of arthralgias. However, the current study was underpowered for a definitive analysis, and larger adequately powered studies are needed. More recently, an inflammatory basis for arthralgia and other AI-associated symptoms has been postulated \[[@B23]\]. Unfortunately, a recently reported targeted anti-inflammatory therapy using omega-3 fatty acids showed no difference over placebo \[[@B24]\]. Overall, these data, along with the current study, suggest that successful interventions to improve overall HRQOL and decrease early discontinuation will likely have to target multiple domains.

If similar findings are validated in larger prospective studies, this information could help inform studies of interventions to improve tolerance of and adherence to therapy. For example, inclusion of patients who develop treatment-emergent symptoms early in the course of AI therapy might enrich for a more "at risk" population that is more likely to benefit from the adherence intervention, thereby increasing the power of the study. To date, prospective trials, such as those evaluating patient educational materials and/or supportive services, have failed to demonstrate improvements in persistence rates of adjuvant endocrine therapy \[[@B25]--[@B27]\]. The reason for the lack of improvement observed in these trials could be due to the inclusion of a general cohort of breast cancer patients, many of whom are unlikely to discontinue treatment, rather than a prespecified group at highest risk for nonpersistence.

Another issue that can result in decreased statistical power to detect changes in PRO measures is the enrollment of a cohort of women with excellent baseline HRQOL and low levels of depression and symptom burden. This is highlighted by the consistent findings in trials of tamoxifen \[[@B28]\] and recent adjuvant \[[@B29], [@B30]\] and neoadjuvant \[[@B31]\] trials of AI therapy that show little change in psychological distress during the study period. Similarly, the ELPh study participants as a group had no significant change in validated measures of depression or anxiety. As in the larger studies discussed earlier, most patients in ELPh also had low rates of depression and anxiety both at baseline and during therapy. Patients with a high pre-existing symptom burden may have more difficulty tolerating therapy compared with those without symptoms, but they are generally not represented in large numbers in clinical trials. Concomitant use of medications for depression and anxiety during study participation might affect these measures over time. However, in the ELPh trial analysis, because of limitations on available data regarding indications for use of concomitant medications as well as low numbers of patients who reported mood issues, analyses on concurrent psychotropic medications use were not performed.

Despite the high incidence of early discontinuation due to patient-reported symptom burden, analyses of the data from the entire cohort and by drug are consistent with the available body of literature describing minimal change in PROs over time in large randomized adjuvant AI trials \[[@B2]--[@B4], [@B29], [@B30], [@B32]--[@B34]\]. What then accounts for the high rate of nonadherence and early discontinuation observed in clinical practice even though the available studies overwhelmingly suggest that overall PROs are minimally affected? To answer this, it is important to understand the difference between commonly used general HRQOL versus symptom-focused PROs. Tools such as the Functional Assessment of Cancer Therapy (FACT)-B and Short Form-36 are psychometrically reliable and valid and measure a variety of domains. Although these commonly used HRQOL tools are able to capture differences between various populations over time (i.e., advanced cancer vs. minimal disease) their ability to capture clinically important differences in trials involving well-balanced populations that are comparing agents with similar toxicity profiles (i.e., adjuvant endocrine therapy) appears limited. In contrast, symptom-specific measures, such as the select items of the endocrine subscale of FACT, are focused on a limited set of adverse symptoms that might allow patients to respond more precisely to symptom severity and allow investigators to discern meaningful differences over time \[[@B35]\]. The large AI adjuvant trials (such as the Arimidex, Tamoxifen Alone or in Combination study; the Intergroup Exemestane Study; and National Cancer Institute of Canada MA.17) exemplify this phenomenon because they found no meaningful difference in overall HRQOL between treatment arms while observing some distinct treatment-specific adverse endocrine symptoms.

Conclusion {#s15}
==========

In the prospective ELPh trial of adjuvant AI therapy for early-stage breast cancer, worsening of multiple treatment-related symptoms during AI therapy predicted AI early discontinuation. If these findings are confirmed in independent trials, early detection of changes in PRO measures could be used clinically to target interventions in patients at high risk for early discontinuation.

See <http://www.TheOncologist.com> for supplemental material available online.
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